Aclidinium Bromide And Formoterol Fumarate has 6 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Drugs That Prolong Qtc Interval, Monoamine Oxidase Inhibitors (Maois), Nonselective Beta-Adrenergic Antagonists. Patients taking Aclidinium Bromide And Formoterol Fumarate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 3
- Moderate
- 3
Major (3)
- Aclidinium Bromide And Formoterol Fumarate + Drugs That Prolong Qtc Interval— Increased risk of ventricular arrhythmias when used with beta-2 agonists. Use with caution.
- Aclidinium Bromide And Formoterol Fumarate + Monoamine Oxidase Inhibitors (Maois)— May potentiate effect of formoterol on cardiovascular system. Use with extreme caution.
- Aclidinium Bromide And Formoterol Fumarate + Nonselective Beta-Adrenergic Antagonists— Beta-blockers may inhibit therapeutic effects of formoterol and produce severe bronchospasm in COPD patients. Use with c…
Moderate (3)
- Aclidinium Bromide And Formoterol Fumarate + Potassium Supplements— ECG changes and hypokalemia from non-potassium-sparing diuretics can be worsened by beta-agonists. Use with caution.
- Aclidinium Bromide And Formoterol Fumarate + Topical Steroids— Concomitant treatment may potentiate hypokalemic effect of beta-adrenergic agonist formoterol. Use with caution.
- Aclidinium Bromide And Formoterol Fumarate + Xanthine Derivatives— Concomitant treatment may potentiate hypokalemic effect of beta-adrenergic agonist formoterol. Use with caution.